Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term effectiveness and safety of ocrelizumab in French patients with progressive multiple sclerosis
2021-006107-15Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Upper limb disability progression at 192 weeks. Started Dec 2021; status: active.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-006107-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006107-15.